^

Health

Reonalgon

, medical expert
Last reviewed: 10.08.2022
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Reonalgon is a drug with antispasmodic and analgesic activity. It is included in the group of artificial anticholinergic substances combined with analgesics. In addition to analgesics, it contains the active ingredient pitofenone.

The drug demonstrates a pronounced analgesic, antispasmodic (similar in effect to papaverine) and anticholinergic (similar in its therapeutic activity to atropine) effect, and besides this, a weak anti-inflammatory effect. [1]

Indications Reonalgon

It is used to eliminate mild to moderate pain that occurs in the case of spasms affecting the smooth muscles of the internal organs:

  • developing accompanied by pain and dysuric disorders of inflammation affecting the urethra, as well as colic in the kidney area;
  • spasms affecting the gastrointestinal tract, gastrointestinal dyskinesia and colic in the liver;
  • dysmenorrhea, which is spastic in nature.

Release form

The release of a therapeutic drug is realized in the form of tablets - 10 pieces inside a cell package; in a box - 1 or 2 packages.

Pharmacodynamics

Metamizole has an intense antipyretic and analgesic effect, which is combined with a weaker antispasmodic and anti-inflammatory effect. These properties develop with the inhibition of PG binding together with internal algogens, an increase in the excitatory threshold in the thalamus, as well as with the conduction of painful intero- and exteroceptive impulses to the central nervous system. In addition, the substance affects the activity of the hypothalamus and the formation of internal pyrogens.

Fenpiverinium demonstrates moderate parasympathetic and ganglion-blocking activity, and in addition, it reduces motility and tone of smooth muscles of the gastrointestinal tract and urethra and bile ducts.

Pitofenone has a papaverine-like effect on extravascular and vascular smooth muscles, which has a pronounced antispasmodic effect. [2]

Pharmacokinetics

Metamizole demonstrates full resorption at high speed. After half an hour from the moment of application, 5% of the serum Cmax values are determined inside the serum. Part of the substance is synthesized with intraplasmic protein.

Inside the body, it participates in intensive biotransformation processes; its basic metabolic elements remain therapeutically active.

Excretion is carried out in the form of metabolic elements together with urine. Only 3% of excreted metamizole has an unchanged form.

The severity of biotransformation is also influenced by the type of acetylation associated with genetic parameters. Some elements are excreted in breast milk.

Dosing and administration

It is necessary to take the tablets orally, after a meal, drinking the medicine with plain water. The sizes of standard daily dosages are 1-2 tablets (it is forbidden to use more than 2 tablets per day). You can take the medication for a maximum of 3 days.

  • Application for children

The drug is not used in persons under 15 years of age.

Use Reonalgon during pregnancy

You can not prescribe Reonalgon during breastfeeding or pregnancy.

Contraindications

The main contraindications:

  • severe intolerance associated with metamizole, pyrazolone derivatives or other elements of the drug;
  • megacolon or obstruction in the gastrointestinal tract;
  • atony affecting the urinary or gallbladder;
  • severe disorders of the liver / kidneys;
  • change in peripheral blood readings (leukopenia or agranulocytosis);
  • pathologies associated with blood (anemia of any nature, as well as neutropenia of an infectious or cytostatic nature);
  • glaucoma;
  • lack of G6FD component;
  • hepatic porphyria;
  • suspicion of the presence of a surgical disease in the active phase;
  • tachyarrhythmia;
  • BA;
  • states similar to collapse;
  • hypertrophy of the prostate, in which there is a tendency to urinary retention.

Side effects Reonalgon

Among the side signs:

  • allergy symptoms: epidermal rash, Quincke's edema, anaphylaxis, urticaria, bronchial spasm, itching, SS and TEN;
  • lesions affecting the digestive system: constipation, xerostomia, as well as exacerbation of an ulcer in the gastrointestinal tract or gastritis;
  • problems with the work of the CVS: tachycardia, palpitation, a decrease in blood pressure values and heart rhythm disturbances;
  • violations of hematopoietic processes: thrombocyto-, granulocyto- or leukopenia, agranulocytosis or anemia;
  • disorders of urinary function: anuria, oliguria or proteinuria, acute renal failure, the acquisition of red urine, as well as tubulointerstitial nephritis;
  • others: hepatitis, dizziness, visual disturbances and hypohidrosis.

Overdose

Poisoning with Reonalgon is usually associated with the action of metamizole in combination with anticholinergic effects; symptoms include respiratory paralysis and kidney / liver dysfunction. Usually, patients have a syndrome that has an allergic-toxic nature, disruption of the gastrointestinal tract and signs of damage to hematopoietic activity; with severe intoxication, symptoms of brain damage occur.

If an overdose is suspected in a patient, the medication should be discontinued immediately and measures should be taken to help quickly excrete it from the body (gastric lavage, induction of vomiting and potentiation of urination). The drug has no antidote, therefore symptomatic actions are used.

Interactions with other drugs

The administration of the drug simultaneously with other medicines should be extremely careful, because it contains metamizole, which induces the activity of enzymes.

Metamizole increases the intraplasmic values of chloroquine, and also weakens the effect and reduces the plasma level of coumarin anticoagulants with cyclosporine.

The drug increases the hematotoxic activity of myelotoxic substances and chloramphenicol.

Sedatives and antipsychotics with tranquilizers potentiate the analgesic effect of metamizole.

Tricyclics with tempidone, allopurinol and oral contraceptives have a destructive effect on the metabolic processes of metamizole and enhance its toxic properties.

Phenylbutazone with barbiturates and other substances that induce the action of intrahepatic microsomal enzymes can weaken the effectiveness of metamizole.

The introduction of Reonalgon in combination with NSAIDs and other analgesics increases the likelihood of toxic symptoms.

Metamizole reduces the intraplasmic parameters of cyclosporin A; combined use with it can be risky if the patient has received tissue transplants.

Storage conditions

Reonalgon must be kept in a place out of the reach of small children. The temperature level is not higher than the 25 ° C mark.

Shelf life

Reonalgon can be applied within a 24-month term from the date of manufacture of the pharmaceutical product.

Analogs

The analogues of drugs are the substances Baralgetas, Spazgan, Realgin with Baralgin, Spazmalgon and Bral with Baralginus, and in addition Spazmogard, Renalgan with Bralangin and Spazmadol. Also on the list are Maxigan, Cyclopar and Trinalgin.

Attention!

To simplify the perception of information, this instruction for use of the drug "Reonalgon" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.